AcquisitionsApr 22, 2026, 06:02 AM
Amneal to Acquire Kashiv BioSciences for up to $1.1B; Raises 2026 Guidance
AI Summary
Amneal Pharmaceuticals announced a definitive agreement to acquire Kashiv BioSciences for an upfront consideration of $750 million ($375M cash, $375M equity) plus up to $350 million in potential milestone payments. This acquisition aims to establish a fully integrated global biosimilars platform, positioning Amneal to capitalize on a projected $300 billion+ global biologics loss-of-exclusivity wave. The company also reported continued growth in preliminary Q1 results and raised its full-year 2026 guidance, expecting the transaction to accelerate growth and diversification.
Key Highlights
- Amneal to acquire Kashiv BioSciences for up to $1.1 billion.
- Initial consideration includes $375 million cash and $375 million equity.
- Up to $350 million in potential regulatory milestone payments.
- Aims to capitalize on $300 billion+ global biologics LOE opportunity.
- Company raises 2026 full-year guidance.